JP2011522835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522835A5 JP2011522835A5 JP2011512705A JP2011512705A JP2011522835A5 JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5 JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- suppressor
- antibody
- isolated
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 10
- 210000001821 Langerhans Cells Anatomy 0.000 claims 8
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 230000001629 suppression Effects 0.000 claims 8
- 210000004027 cells Anatomy 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 3
- 102100003268 CD14 Human genes 0.000 claims 2
- 101700027514 CD14 Proteins 0.000 claims 2
- 102100013082 CD1A Human genes 0.000 claims 2
- 101700015984 CD1A Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 102100016492 CD34 Human genes 0.000 claims 1
- 108060001251 CD34 Proteins 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 108030007211 EC 3.4.21.78 Proteins 0.000 claims 1
- 108030007212 EC 3.4.21.79 Proteins 0.000 claims 1
- 102100004383 GZMA Human genes 0.000 claims 1
- 102100004391 GZMB Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 1
Claims (13)
- サプレッサーT細胞を作製する方法であって、
単離したランゲルハンス細胞(LC)前駆体を、GM−CSF、Flt3−L及びTNFαの存在下で培養してLCを作製するステップと、得られたLCと単離したT細胞とを、抗CD8抗体の存在下で、サプレッサーT細胞が生成される条件下で共培養するステップとを含む方法。 - 抗CD8抗体が、ウイルスに対する免疫応答に影響することなく、移植(engraft)された器官に対する免疫応答を下方制御する、請求項1に記載の方法。
- 単離したT細胞が、高結合活性の抗原特異的ナイーブT細胞である、請求項1又は2に記載の方法。
- ランゲルハンス細胞が、CD1a+CD14−ランゲルハンス細胞である、請求項1〜3のいずれかに記載の方法。
- CD1a+CD14−ランゲルハンス細胞が、セルソーティング(cell sorting)により得られる、請求項4に記載の方法。
- ランゲルハンス細胞が、CD34+ 造血前駆細胞(HPC)をGM−CSF、Flt3−L及びTNFαの存在下で9〜10日間培養することによりインビトロで生成される、請求項1〜5のいずれかに記載の方法。
- 抗CD8抗体が、cM−T807、T8、RPA−T8、HIT8a、Leu2、T8及びOKT8から選択される、請求項1〜6のいずれかに記載の方法。
- 抗CD8抗体が、0.5〜5,000ng/mlで培養物中に提供される、請求項1〜7のいずれかに記載の方法。
- 単離した単球を、GM−CSF及びIFN−α−2bの存在下で培養して単離樹状細胞(IFN−DC)を作製するステップと、抗CD8抗体の存在下で、グランザイムAの減少、グランザイムBの減少、パーフォリンの減少、IL−2、IFN−γ若しくはこれら両方の分泌量の減少、IL−10の分泌又はそれらの組合せにより測定されるサプレッサーT細胞が生成される条件下で、前記IFN−DCと単離したT細胞とを共培養するステップとを含む、サプレッサーT細胞を作製する方法。
- 移植拒絶を低減する組成物であって、その他の免疫応答を消失させることなく移植拒絶を低減するのに十分な有効量のサプレッサーT細胞を含み、前記サプレッサーT細胞が、抗CD8抗体の存在下で、サプレッサーT細胞が生成される条件下で成熟ランゲルハンス細胞(LC)と共培養された単離末梢血T細胞から生成される組成物。
- 抗CD8抗体が、cM−T807、T8、RPA−T8、HIT8a、Leu2、T8及びOKT8から選択される、請求項10に記載の組成物。
- 抗CD8抗体が、0.5〜5,000ng/mlで培養物中に提供される、請求項10又は11に記載の組成物。
- サプレッサーT細胞が、凍結しており、使用前に注射用の媒体に再懸濁される、請求項10〜12のいずれかに記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5964708P | 2008-06-06 | 2008-06-06 | |
US61/059,647 | 2008-06-06 | ||
PCT/US2009/046464 WO2009149382A2 (en) | 2008-06-06 | 2009-06-05 | Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011522835A JP2011522835A (ja) | 2011-08-04 |
JP2011522835A5 true JP2011522835A5 (ja) | 2012-07-19 |
Family
ID=41398905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011512705A Pending JP2011522835A (ja) | 2008-06-06 | 2009-06-05 | 抗cd8抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性cd8+t細胞の生成を導く |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090304659A1 (ja) |
EP (1) | EP2297204A4 (ja) |
JP (1) | JP2011522835A (ja) |
KR (1) | KR20110025812A (ja) |
CN (1) | CN102112491A (ja) |
AU (1) | AU2009255999A1 (ja) |
BR (1) | BRPI0915582A2 (ja) |
CA (1) | CA2728772A1 (ja) |
IL (1) | IL209798A0 (ja) |
MX (1) | MX2010013265A (ja) |
NZ (1) | NZ590197A (ja) |
TW (1) | TW201000130A (ja) |
WO (1) | WO2009149382A2 (ja) |
ZA (1) | ZA201100061B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5825966B2 (ja) * | 2011-10-11 | 2015-12-02 | 株式会社日本バイオセラピー研究所 | Cd56陽性t細胞増強方法 |
US10092597B2 (en) | 2014-01-14 | 2018-10-09 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice |
WO2018085897A1 (en) * | 2016-11-14 | 2018-05-17 | Murdoch Childrens Research Institute | Transplant rejection assay |
JP7304846B2 (ja) * | 2017-07-24 | 2023-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗cd8抗体およびその使用 |
WO2020250940A1 (ja) | 2019-06-11 | 2020-12-17 | 小野薬品工業株式会社 | 免疫抑制剤 |
WO2022017370A1 (zh) * | 2020-07-21 | 2022-01-27 | 苏州智核生物医药科技有限公司 | Cd8结合多肽及其用途 |
CN112156110B (zh) * | 2020-09-15 | 2022-10-14 | 上海交通大学医学院 | Cd8+抑制性t细胞在免疫调节中的应用及诱导方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5178858A (en) * | 1987-12-02 | 1993-01-12 | Reichert Thomas A | Method for prevention of graft versus host disease |
CA1339840C (en) * | 1988-12-16 | 1998-04-28 | Kenneth Kortright | Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics |
US5601828A (en) * | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
GB8912497D0 (en) * | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
HUT65550A (en) * | 1990-11-23 | 1994-06-28 | Coulter Corp | Method and apparatus for examination of cells groups |
US6911220B1 (en) * | 1992-02-19 | 2005-06-28 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
US5876708A (en) * | 1992-02-19 | 1999-03-02 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
ATE432339T1 (de) * | 1996-04-05 | 2009-06-15 | Univ South Alabama | Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10 |
EP2301567A1 (en) * | 1997-02-28 | 2011-03-30 | Enzo Therapeutics, Inc. | Selective immune down regulation (SIDR) for transplantation |
US6803036B1 (en) * | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
US20040022761A1 (en) * | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
WO2004029208A2 (en) * | 2002-09-27 | 2004-04-08 | Bioe, Inc. | Cell separation compositions and methods |
WO2004083244A2 (en) * | 2003-03-19 | 2004-09-30 | Isogenis, Inc. | Specific inhibition of allograft rejection |
GB0314461D0 (en) * | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
CA2691346A1 (en) * | 2006-06-30 | 2008-01-10 | Baylor Research Institute | Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells |
-
2009
- 2009-06-05 CN CN2009801301198A patent/CN102112491A/zh active Pending
- 2009-06-05 US US12/479,349 patent/US20090304659A1/en not_active Abandoned
- 2009-06-05 JP JP2011512705A patent/JP2011522835A/ja active Pending
- 2009-06-05 KR KR1020117000123A patent/KR20110025812A/ko not_active Application Discontinuation
- 2009-06-05 BR BRPI0915582A patent/BRPI0915582A2/pt not_active IP Right Cessation
- 2009-06-05 EP EP09759540.9A patent/EP2297204A4/en not_active Withdrawn
- 2009-06-05 CA CA2728772A patent/CA2728772A1/en not_active Abandoned
- 2009-06-05 MX MX2010013265A patent/MX2010013265A/es active IP Right Grant
- 2009-06-05 AU AU2009255999A patent/AU2009255999A1/en not_active Abandoned
- 2009-06-05 NZ NZ590197A patent/NZ590197A/xx not_active IP Right Cessation
- 2009-06-05 WO PCT/US2009/046464 patent/WO2009149382A2/en active Application Filing
- 2009-06-06 TW TW098118952A patent/TW201000130A/zh unknown
-
2010
- 2010-12-06 IL IL209798A patent/IL209798A0/en unknown
-
2011
- 2011-01-03 ZA ZA2011/00061A patent/ZA201100061B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011522835A5 (ja) | ||
AU2020233702B2 (en) | Methods of preparing anti-human papillomavirus antigen T cells | |
Van Driessche et al. | Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial | |
JP2023052777A (ja) | 末梢免疫機能を調節するための方法及び組成物 | |
Bi et al. | Molecular regulation of NK cell maturation | |
JP6182175B2 (ja) | 樹状細胞の製造方法 | |
CA2602434A1 (en) | Dendritic cell compositions and methods | |
JP2012521215A5 (ja) | ||
Schmidt et al. | Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation | |
US20150125956A1 (en) | Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same | |
Roberts et al. | TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells | |
Evans et al. | The trophic life cycle stage of the opportunistic fungal pathogen Pneumocystis murina hinders the ability of dendritic cells to stimulate CD4+ T cell responses | |
Dragicevic et al. | Signaling through Toll-like receptor 3 and Dectin-1 potentiates the capability of human monocyte-derived dendritic cells to promote T-helper 1 and T-helper 17 immune responses | |
LeÓn et al. | Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease | |
Abediankenari et al. | Comparison of several maturation inducing factors in dendritic cell differentiation | |
Kolanowski et al. | Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ–matured type I dendritic cells for immunotherapy | |
CN110607276A (zh) | 高效扩增脐带血nk细胞的无血清培养方法 | |
De Felice et al. | Hematopoietic, mesenchymal, and immune cells are more enhanced in bone marrow than in peripheral blood from granulocyte colony-stimulating factor primed healthy donors | |
WO2014126250A1 (ja) | G-csfを用いた樹状細胞の調製方法 | |
Yi et al. | 3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E 2 are a promising alternative for cancer immunotherapy | |
CN113444688B (zh) | 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物 | |
US8076132B2 (en) | Dendritic cell tumor injection (DCTI) therapy | |
Li et al. | The regulatory role of dendritic cells in the immune tolerance | |
Heystek et al. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone | |
Futalan et al. | Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy |